GSK and CureVac to Restructure Collaboration into New Licensing

 

• GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations

• CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced

https://www.biospace.com/article/releases/gsk-and-curevac-to-restructure-collaboration-into-new-licensing-agreement/